BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 18, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Vincerx's antibody-drug conjugate VIP-943 receives FDA clearance for phase I study in AML
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Vincerx's antibody-drug conjugate VIP-943 receives FDA clearance for phase I study in AML
Aug. 23, 2023
No Comments
Vincerx Pharma Inc. has received IND clearance from the FDA to initiate a phase I trial for VIP-943, an antibody-drug conjugate (ADC) for acute...
BioWorld Science
Regulatory
Cancer
Antibody-drug conjugate
Immuno-oncology
FDA
IND
